Compare HWKN & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HWKN | BEAM |
|---|---|---|
| Founded | 1938 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.0B |
| IPO Year | 1995 | 2019 |
| Metric | HWKN | BEAM |
|---|---|---|
| Price | $139.60 | $25.19 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 12 |
| Target Price | ★ $200.00 | $50.75 |
| AVG Volume (30 Days) | 178.2K | ★ 2.6M |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.46% | N/A |
| EPS Growth | N/A | ★ 82.31 |
| EPS | ★ 3.91 | N/A |
| Revenue | ★ $1,083,696,000.00 | $24,000.00 |
| Revenue This Year | $12.37 | N/A |
| Revenue Next Year | $6.30 | $33.77 |
| P/E Ratio | $35.63 | ★ N/A |
| Revenue Growth | 11.21 | ★ 33.33 |
| 52 Week Low | $117.98 | $15.60 |
| 52 Week High | $186.15 | $38.26 |
| Indicator | HWKN | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 38.53 | 30.23 |
| Support Level | $130.08 | $24.80 |
| Resistance Level | $152.94 | $33.32 |
| Average True Range (ATR) | 5.11 | 1.99 |
| MACD | 0.67 | -0.94 |
| Stochastic Oscillator | 38.85 | 1.83 |
Hawkins Inc manufactures and sells a variety of chemicals and ingredients. The firm organizes itself into three segments based on the product type. The Industrial Solutions segment, provides industrial chemicals, products and services to industries such as industrial manufacturing, chemical processing, electronics, energy, plating, and surface finishing. The water treatment segment, which generates the majority of revenue sells chemicals and equipment used to treat potable water, municipal and industrial wastewater, industrial process water, and non-residential swimming pool water. Food and Health Sciences segment specializes in processing and formulation solutions as well as ingredient distribution to manufacturers in the nutrition, food, pharmaceutical, and agricultural markets.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.